The Combination of Umbralisib Plus Ublituximab is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global UNITY-NHL Trial

Drug Category : Array
Conference Category : Array
Lead Author : Chavez J, et al.
Published Date : 11/12/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/12/ASH2021ChavezUNHL.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top